Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

2.

MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?

Feduccia AA, Mithoefer MC.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):221-228. doi: 10.1016/j.pnpbp.2018.03.003. Epub 2018 Mar 7. Review.

3.

Toxicity, Amphetamine.

Vasan S, Olango GJ.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2017 Dec 11.

4.

The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.

Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F.

Front Psychiatry. 2017 Nov 20;8:240. doi: 10.3389/fpsyt.2017.00240. eCollection 2017. Review.

5.

MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent 'Ecstasy' users.

Roberts CA, Quednow BB, Montgomery C, Parrott AC.

Neurosci Biobehav Rev. 2018 Jan;84:470-482. doi: 10.1016/j.neubiorev.2017.07.015. Epub 2017 Aug 8. Review.

6.

Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective.

Sessa B.

Neurotherapeutics. 2017 Jul;14(3):741-749. doi: 10.1007/s13311-017-0531-1. Review.

7.

Ecstasy (MDMA) and its effects on kidneys and their treatment: a review.

Bora F, Yılmaz F, Bora T.

Iran J Basic Med Sci. 2016 Nov;19(11):1151-1158. Review.

8.

Consequences of adolescent use of alcohol and other drugs: Studies using rodent models.

Spear LP.

Neurosci Biobehav Rev. 2016 Nov;70:228-243. doi: 10.1016/j.neubiorev.2016.07.026. Epub 2016 Jul 30. Review.

9.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

10.

Illicit Drug Dependence.

Degenhardt L, Stockings E, Strang J, Marsden J, Hall WD.

In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, editors. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Mar 14. Chapter 6.

11.

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.

Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA.

Front Neurosci. 2016 Apr 19;10:153. doi: 10.3389/fnins.2016.00153. eCollection 2016. Review.

12.

Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.

Roberts CA, Jones A, Montgomery C.

Neurosci Biobehav Rev. 2016 Apr;63:158-67. doi: 10.1016/j.neubiorev.2016.02.003. Epub 2016 Feb 6. Review.

13.

Neuroimaging in moderate MDMA use: A systematic review.

Mueller F, Lenz C, Steiner M, Dolder PC, Walter M, Lang UE, Liechti ME, Borgwardt S.

Neurosci Biobehav Rev. 2016 Mar;62:21-34. doi: 10.1016/j.neubiorev.2015.12.010. Epub 2015 Dec 30. Review.

14.

Mephedrone related fatalities: a review.

Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S.

Eur Rev Med Pharmacol Sci. 2015 Oct;19(19):3777-90. Review.

15.

[Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].

Szabó A, Kazai A, Frecska E, Brys Z.

Neuropsychopharmacol Hung. 2015 Sep;17(3):120-8. Review. Hungarian.

16.

Effects of addictive drugs on adult neural stem/progenitor cells.

Xu C, Loh HH, Law PY.

Cell Mol Life Sci. 2016 Jan;73(2):327-48. doi: 10.1007/s00018-015-2067-z. Epub 2015 Oct 14. Review.

17.

The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Kamilar-Britt P, Bedi G.

Neurosci Biobehav Rev. 2015 Oct;57:433-46. doi: 10.1016/j.neubiorev.2015.08.016. Epub 2015 Sep 25. Review.

18.

MDMA for the treatment of mood disorder: all talk no substance?

Patel R, Titheradge D.

Ther Adv Psychopharmacol. 2015 Jun;5(3):179-88. doi: 10.1177/2045125315583786. Review.

19.

Cathinone neurotoxicity ("The "3Ms").

Karch SB.

Curr Neuropharmacol. 2015 Jan;13(1):21-5. doi: 10.2174/1570159X13666141210225009. Review.

20.

Synthetic cathinones: a new public health problem.

Karila L, Megarbane B, Cottencin O, Lejoyeux M.

Curr Neuropharmacol. 2015 Jan;13(1):12-20. doi: 10.2174/1570159X13666141210224137. Review.

Supplemental Content

Loading ...
Support Center